Clinical Trials | November 28, 2025
Renalys Pharma reports major phase III success for Sparsentan in Japanese IgA nephropathy patients
The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio
